The Effects of Dupilumab on Allergic Contact Dermatitis

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions

Allergic Contact Dermatitis

Interventions

DRUG

Dupilumab

See arm/group description

Trial Locations (1)

Brigham and Women's Hospital, Department of Dermatology, Boston

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Brigham and Women's Hospital

OTHER